Literature DB >> 28569345

Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.

N Betrouni1, S Boukris2, F Benzaghou2.   

Abstract

Vascular targeted photodynamic therapy (VTP) with WST11 is a novel non-thermal focal treatment for localized prostate cancer that has shown favorable and early efficacy results in previously published studies. In this work, we investigate the efficiency of automatic dosimetric treatment planning. An action model established in a previous study was used in an image-guided optimization scheme to define the personalized optimal light dose for each patient. The calculated light dose is expressed as the number of optical cylindrical fibers to be used, their positions according to an external insertion grid, and the lengths of their diffuser parts. Evaluation of the method was carried out on data collected from 17 patients enrolled in two multi-centric clinical trials. The protocol consisted of comparing the method-simulated necrosis to the result observed on day 7 MR enhanced images. The method performances showed that the final result can be estimated with an accuracy of 10%, corresponding to a margin of 3 mm. In addition, this process was compatible with clinical conditions in terms of calculation times. The overall process took less than 10 min. Different aspects of the VTP procedure were already defined and optimized. Personalized treatment planning definition remained as an issue needing further investigation. The method proposed herein completes the standardization of VTP and opens new pathways for the clinical development of the technique.

Entities:  

Keywords:  Image guided procedure; Photodynamic therapy; Prostate cancer; Treatment planning

Mesh:

Substances:

Year:  2017        PMID: 28569345     DOI: 10.1007/s10103-017-2241-7

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  25 in total

1.  System for interstitial photodynamic therapy with online dosimetry: first clinical experiences of prostate cancer.

Authors:  Johannes Swartling; Johan Axelsson; Göran Ahlgren; Karl Mikael Kälkner; Sten Nilsson; Sune Svanberg; Katarina Svanberg; Stefan Andersson-Engels
Journal:  J Biomed Opt       Date:  2010 Sep-Oct       Impact factor: 3.170

2.  Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer.

Authors:  C M Moore; T R Nathan; W R Lees; C A Mosse; A Freeman; M Emberton; S G Bown
Journal:  Lasers Surg Med       Date:  2006-06       Impact factor: 4.025

3.  Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.

Authors:  Abdel-Rahmène Azzouzi; Sébastien Vincendeau; Eric Barret; Antony Cicco; François Kleinclauss; Henk G van der Poel; Christian G Stief; Jens Rassweiler; Georg Salomon; Eduardo Solsona; Antonio Alcaraz; Teuvo T Tammela; Derek J Rosario; Francisco Gomez-Veiga; Göran Ahlgren; Fawzi Benzaghou; Bertrand Gaillac; Billy Amzal; Frans M J Debruyne; Gaëlle Fromont; Christian Gratzke; Mark Emberton
Journal:  Lancet Oncol       Date:  2016-12-20       Impact factor: 41.316

4.  Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.

Authors:  Timothy C Zhu; Jarod C Finlay; Stephen M Hahn
Journal:  J Photochem Photobiol B       Date:  2004-12-02       Impact factor: 6.252

5.  Photodosimetry of interstitial light delivery to solid tumors.

Authors:  M C Fenning; D Q Brown; J D Chapman
Journal:  Med Phys       Date:  1994-07       Impact factor: 4.071

6.  Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide.

Authors:  Masoom A Haider; Sean R H Davidson; Ashwini V Kale; Robert A Weersink; Andrew J Evans; Ants Toi; Mark R Gertner; Arjen Bogaards; Brian C Wilson; Joseph L Chin; Mostafa Elhilali; John Trachtenberg
Journal:  Radiology       Date:  2007-05-16       Impact factor: 11.105

Review 7.  Focal therapy of prostate cancer: energies and procedures.

Authors:  G Bozzini; P Colin; P Nevoux; A Villers; S Mordon; N Betrouni
Journal:  Urol Oncol       Date:  2012-07-12       Impact factor: 3.498

8.  Elastic image registration for guiding focal laser ablation of prostate cancer: preliminary results.

Authors:  Nasr Makni; Philippe Puech; Pierre Colin; Abdelrahmene Azzouzi; Serge Mordon; Nacim Betrouni
Journal:  Comput Methods Programs Biomed       Date:  2012-05-09       Impact factor: 5.428

9.  Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer.

Authors:  Sean R H Davidson; Robert A Weersink; Masoom A Haider; Mark R Gertner; Arjen Bogaards; David Giewercer; Avigdor Scherz; Michael D Sherar; Mostafa Elhilali; Joseph L Chin; John Trachtenberg; Brian C Wilson
Journal:  Phys Med Biol       Date:  2009-03-20       Impact factor: 3.609

10.  In vivo optical characterization of human prostate tissue using near-infrared time-resolved spectroscopy.

Authors:  Tomas Svensson; Stefan Andersson-Engels; Margrét Einarsdóttír; Katarina Svanberg
Journal:  J Biomed Opt       Date:  2007 Jan-Feb       Impact factor: 3.170

View more
  7 in total

1.  Automatic interstitial photodynamic therapy planning via convex optimization.

Authors:  Abdul-Amir Yassine; William Kingsford; Yiwen Xu; Jeffrey Cassidy; Lothar Lilge; Vaughn Betz
Journal:  Biomed Opt Express       Date:  2018-01-30       Impact factor: 3.732

2.  Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells.

Authors:  Yan Baglo; Barry J Liang; Robert W Robey; Suresh V Ambudkar; Michael M Gottesman; Huang-Chiao Huang
Journal:  Cancer Lett       Date:  2019-05-06       Impact factor: 8.679

Review 3.  A promising anticancer drug: a photosensitizer based on the porphyrin skeleton.

Authors:  Qizhi Zhang; Jun He; Wenmei Yu; Yanchun Li; Zhenhua Liu; Binning Zhou; Yunmei Liu
Journal:  RSC Med Chem       Date:  2020-02-25

Review 4.  Photodynamic Therapy for Cancer: What's Past is Prologue.

Authors:  Michael R Hamblin
Journal:  Photochem Photobiol       Date:  2020-01-07       Impact factor: 3.421

Review 5.  Clinical development of photodynamic agents and therapeutic applications.

Authors:  Rengarajan Baskaran; Junghan Lee; Su-Geun Yang
Journal:  Biomater Res       Date:  2018-09-26

6.  Effects of patient-specific treatment planning on eligibility for photodynamic therapy of deep tissue abscess cavities: retrospective Monte Carlo simulation study.

Authors:  Zihao Li; Lam Nguyen; David A Bass; Timothy M Baran
Journal:  J Biomed Opt       Date:  2022-02       Impact factor: 3.170

Review 7.  Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.

Authors:  Qin Xue; Jingliang Zhang; Jianhua Jiao; Weijun Qin; Xiaojian Yang
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.